Literature DB >> 20190892

Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia.

Eleni Galanis1, Linda Hoang, Pamela Kibsey, Muhammad Morshed, Peter Phillips.   

Abstract

The environmental fungus Cryptococcus gattii emerged on Vancouver Island, British Columbia (BC), in 1999. By the end of 2006, it led to 176 cases and eight deaths - one of the highest burdens of C gattii disease worldwide. The present paper describes three cases, and the BC experience in the diagnosis and management of this infection. All three cases presented with pulmonary findings, including cryptococcomas and infiltrates. One also presented with brain cryptococcomas. Cases were diagnosed by chest and brain imaging, and laboratory evidence including serum or cerebrospinal fluid cryptococcal antigen detection and culture of respiratory or cerebrospinal fluid specimens. Genotyping of fungal isolates confirmed infection with C gattii VGIIa. Pulmonary cases were treated with fluconazole. One patient with central nervous system disease was treated with amphotericin B followed by fluconazole. Although this infection remains rare, clinicians should be aware of it in patients with a compatible clinical presentation who are either living in or returning from a trip to BC.

Entities:  

Keywords:  Case series; Cryptococcus gattii; Diagnosis; Treatment

Year:  2009        PMID: 20190892      PMCID: PMC2690522          DOI: 10.1155/2009/719659

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  35 in total

1.  Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia.

Authors:  Craig Stephen; S Lester; W Black; M Fyfe; Stephen Raverty
Journal:  Can Vet J       Date:  2002-10       Impact factor: 1.008

2.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

3.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

4.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Authors:  P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

5.  False-negative cryptococcal antigen test.

Authors:  A M Stamm; S S Polt
Journal:  JAMA       Date:  1980-09-19       Impact factor: 56.272

6.  Optic nerve sheath decompression for visual loss in patients with acquired immunodeficiency syndrome and cryptococcal meningitis with papilledema.

Authors:  J A Garrity; D C Herman; R Imes; P Fries; C F Hughes; R J Campbell
Journal:  Am J Ophthalmol       Date:  1993-10-15       Impact factor: 5.258

7.  Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki.

Authors:  Y Yamamoto; S Kohno; H Koga; H Kakeya; K Tomono; M Kaku; T Yamazaki; M Arisawa; K Hara
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

8.  First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak.

Authors:  Arlo Upton; James A Fraser; Sarah E Kidd; Camille Bretz; Karen H Bartlett; Joseph Heitman; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

9.  Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City.

Authors:  B P Currie; L F Freundlich; A Casadevall
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. The Cryplococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; R J Kuykendall; R W Pinner
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

View more
  17 in total

Review 1.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

2.  Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Ahmed Khalil; Jessica A Edwards; Chad A Rappleye; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2014-12-10       Impact factor: 3.641

Review 3.  Management of Cryptococcus gattii meningoencephalitis.

Authors:  Carlos Franco-Paredes; Tanea Womack; Teri Bohlmeyer; Brenda Sellers; Allison Hays; Kalpesh Patel; Jairo Lizarazo; Shawn R Lockhart; Wajid Siddiqui; Kieren A Marr
Journal:  Lancet Infect Dis       Date:  2014-11-26       Impact factor: 25.071

4.  Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts.

Authors:  Oscar Zaragoza; Ana C Mesa-Arango; Alicia Gómez-López; Leticia Bernal-Martínez; Juan Luis Rodríguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

Review 5.  Cryptococcus gattii comparative genomics and transcriptomics: a NIH/NIAID White Paper.

Authors:  V Chaturvedi; W C Nierman
Journal:  Mycopathologia       Date:  2011-12-17       Impact factor: 2.574

6.  Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene.

Authors:  Kassandre Leongson; Vincent Cousineau-Côté; Mathieu Goupil; Francine Aumont; Serge Sénéchal; Louis Gaboury; Paul Jolicoeur; James W Kronstad; Louis de Repentigny
Journal:  Infect Immun       Date:  2013-01-22       Impact factor: 3.441

7.  Successful Isavuconazole Salvage Therapy for a Cryptococcus deuterogattii (AFLP6/VGII) Disseminated Infection in a European Immunocompetent Patient.

Authors:  Maria Soledad Cuetara; Juan José Jusdado Ruiz-Capillas; Maria Pilar Nuñez-Valentin; Elena Rodríguez Garcia; Elena Garcia-Benayas; Ricardo Rojo-Amigo; Jose Carlos Rodriguez-Gallego; Ferry Hagen; María Francisca Colom
Journal:  Mycopathologia       Date:  2021-06-11       Impact factor: 2.574

8.  Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant.

Authors:  Emily W Bratton; Nada El Husseini; Cody A Chastain; Michael S Lee; Charles Poole; Til Stürmer; Jonathan J Juliano; David J Weber; John R Perfect
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

9.  Fatal disseminated Cryptococcus gattii infection in New Mexico.

Authors:  Carla J Walraven; Wendy Gerstein; Sarah E Hardison; Floyd Wormley; Shawn R Lockhart; Julie R Harris; Annette Fothergill; Brian Wickes; Julie Gober-Wilcox; Larry Massie; T S Neil Ku; Carolina Firacative; Wieland Meyer; Samuel A Lee
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

10.  Recognition and diagnosis of Cryptococcus gattii infections in the United States.

Authors:  Sally Ann Iverson; Tom Chiller; Susan Beekmann; Philip M Polgreen; Julie Harris
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.